Moderna's Analyst Day Arrives With Two Bullish Targets, a GSK Truce and a Fresh Profit in Hand
Published on 11/12/2026 at 14:02 | Editorial boerse-global.de
Moderna's stock came under pressure on Tuesday, with media reports pointing to profit-taking and valuation jitters following the sharp rally that greeted its quarterly results. Weakness across the broader market added to the drag, and no fresh company-specific setback was cited as the trigger.
The pullback lands on the morning of the company's analyst day, which is scheduled to begin at 9:00 a.m. EST. It also follows a busy stretch in which Moderna raised its guidance, settled long-running patent litigation and added two Canadian product approvals — while two Wall Street houses lifted their price targets but stopped short of a shared verdict on the shares.
Two Targets, Two Convictions
Goldman Sachs on Monday raised its price target to $195 from $137 while keeping a neutral rating, according to media reports. Piper Sandler moved its target to $305 from $230 the same day and stayed at overweight, taking the more confident line.
The split is the interesting part. A higher target can signal greater faith in the trajectory without committing to an aggressive call on the stock, which puts the reasoning behind a re-rating ahead of its direction. For Moderna, both the commercial business and the product pipeline offer grounds for that kind of rethink — and the two houses' differing verdicts frame the real valuation question: how much weight belongs to earnings already booked, and how much to the promise of future products.
Should investors sell immediately? Or is it worth buying Moderna?
A 42% Risk Reduction, and a Fifth Approval
Moderna and Merck reported on October 22 that intismeran autogene combined with KEYTRUDA cut the risk of recurrence or death by 42% versus KEYTRUDA alone in the Phase 3 INTerpath-001 trial. The companies said they are working toward regulatory filings, giving investors a concrete clinical milestone with the next leg of the journey running through that filing work.
On the approval side, CBC reported on August 5 that the FDA had cleared the seasonal influenza vaccine mFLUSIVA, Moderna's fifth licensed product worldwide. The structural argument for the stock rests on that progression: development gains acquire economic weight only when they become approved products and, eventually, revenue.
Guidance Raised, and a Profit to Match
Alongside its quarterly report, Moderna lifted its revenue growth outlook to 15%–25%, up from a prior expectation of as much as 10%. The company now sees full-year 2026 growth in that range.
Third-quarter 2026 revenue came in at $1.3 billion, with net income of $0.2 billion under US GAAP and diluted earnings of $0.38 per share. Reuters put the net profit figure at $162 million. Moderna also trimmed its operating expense outlook by roughly $0.2 billion and raised its projected year-end liquidity to $8.1–8.3 billion.
That combination — clinical progress alongside a positive quarter — makes the investment case more demanding but also more tangible. Operating results can now be weighed against expectations for future products, a more informative exercise than judging a trial readout or a price-target hike in isolation. The optimistic reading gains force if Moderna delivers on the growth outlook and keeps the pipeline moving; the higher targets acquire substance only if clinical advances and financial results sustain each other over time.
Moderna at a turning point? This analysis reveals what investors need to know now.
A Royalty-Free Truce, and a Canadian First
On the legal front, GSK settled its patent disputes with Moderna in the US and Europe on November 6, according to media reports. The fights concerned the Spikevax, mNEXSPIKE and mResvia vaccines. The two companies granted each other patent licences covering infectious diseases, and no payments are due under those licences.
A day earlier, Health Canada approved Moderna's seasonal influenza vaccine mFLUSIVA and its combined influenza/COVID-19 shot mCOFLU for adults aged 50 and over. By the company's account, Canada is the first country to clear both products.
Ad
Moderna Stock: New Analysis - 12 November
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
